Core Viewpoint - Kaskela Law LLC is investigating the buyout of Green Dot Corp. to assess whether the offer is fair to shareholders or undervalues the company's shares [1][3]. Group 1: Buyout Details - On November 24, 2025, Green Dot announced its acquisition by Smith Ventures and CommerceOne Financial Corporation, with each share of Green Dot common stock to be exchanged for $8.11 in cash and 0.2215 shares of a new publicly traded bank holding company [2]. Group 2: Investigation Focus - The investigation aims to determine if Green Dot investors are receiving adequate financial consideration for their shares, highlighting potential conflicts of interest that may render the sales process unfair to shareholders [3].

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1] Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc. and covers investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1] - Allegations include that Ultragenyx executives made false statements about the reliability of data from the Phase III Orbit study, which purportedly minimized the risks of not achieving statistically significant results [1] - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, leading to a stock price drop of over 25% [1] - A subsequent announcement on December 29, 2025, revealed that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, resulting in a further stock price decline of over 42% [1] Group 2: Company Background - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [1] - The company’s optimism regarding the Phase III Orbit study was reportedly misplaced, as it did not adequately communicate the risks associated with its Phase II results, which lacked a placebo control group [1] Group 3: Legal Process and Firm Information - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit [1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]

Core Viewpoint - Eos Energy Enterprises is under investigation for potential violations of federal securities laws, which may impact investors who have suffered losses [1] Group 1 - The Law Offices of Howard G. Smith are representing Eos Energy investors in this investigation [1] - Investors who experienced losses in Eos Energy Enterprises are encouraged to contact the law firm to discuss potential claims for recovery [1]

Core Viewpoint - Eos Energy Enterprises is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Group 1 - Glancy Prongay Wolke & Rotter LLP has initiated an investigation on behalf of Eos Energy investors [1] - The investigation focuses on the possible legal violations by Eos Energy Enterprises [1] - Investors who lost money on Eos Energy are encouraged to inquire about pursuing claims to recover their losses [1]

Core Viewpoint - Levi & Korsinsky has initiated an investigation into Eos Energy Enterprises, Inc. for potential violations of federal securities laws related to inaccurate statements about production capacity and product performance [1][2]. Group 1: Investigation Details - The investigation is focused on whether Eos Energy's claims regarding battery efficiency, production outlook, and commercial pipeline were based on reasonable grounds at the time they were made [3]. - During the Q3 2025 earnings call, COO John Mahaz reported that the automated battery line operated at 15% capacity utilization of its full 2-gigawatt potential, and the company anticipated shipping three times the Q3 volume in Q4 [2]. - CEO Joe Mastrangelo claimed that the company's round-trip efficiency was "in the mid-80s to the low 90s" across a wide operating range, asserting that no other technology could deliver similar performance [2]. Group 2: Financial Performance - Eos Energy's Q4 2025 revenue was reported at $58 million, significantly below management's projections, and the 2026 guidance was materially lower than previous expectations [2].

Core Viewpoint - Lakeland Industries, Inc. is facing a securities fraud class action lawsuit due to alleged undisclosed operational issues and misleading financial guidance that led to significant investor losses [1] Group 1: Lawsuit Details - The lawsuit claims that from December 1, 2023, to December 9, 2025, Lakeland failed to disclose significant issues with its Pacific Helmets and Jolly businesses, including shipping delays and production problems [1] - Defendants allegedly overstated the positive impact of these businesses on Lakeland's financial results and the overall strength of their operations [1] - The complaint indicates that Lakeland's financial results were deteriorating due to tariff-related challenges, certification delays, and material flow issues in acquired businesses [1] Group 2: Misleading Statements - The lawsuit asserts that the defendants overstated the effectiveness of their tariff mitigation measures and their mergers and acquisitions strategy [1] - As a result of these issues, the financial guidance provided by the defendants was deemed unreliable [1] - Positive statements made by the defendants regarding the company's business and prospects were considered materially misleading and lacked a reasonable basis [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inovio Pharmaceuticals due to allegations of violations of federal securities laws related to misleading statements and inadequate disclosures regarding the company's manufacturing and regulatory processes for its INO-3107 treatment [4][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered significant losses in Inovio between October 10, 2023, and December 26, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Inovio, with a deadline of April 7, 2026, for investors to seek the role of lead plaintiff [4]. - The complaint alleges that Inovio and its executives made false and misleading statements regarding the manufacturing of the CELLECTRA device and the prospects of the INO-3107 Biologics License Application (BLA) [6]. Group 2: Regulatory and Financial Impact - The FDA accepted Inovio's BLA for INO-3107 on a standard review timeline, indicating that the company did not provide sufficient information for accelerated approval [7]. - Following the FDA's announcement, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 per share on December 29, 2025 [8]. - Inovio plans to request a meeting with the FDA to discuss potential pathways for pursuing accelerated approval despite the current setback [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Navan, Inc. due to allegations of violations of federal securities laws related to misleading statements in the company's IPO documents, which led to significant losses for investors [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is reminding investors of the April 24, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Navan [4]. - The complaint alleges that Navan and its executives made false and misleading statements and failed to disclose increased "sales and marketing" expenses at the time of the IPO [6]. - The value of Navan's shares declined dramatically, trading as low as $9.01 per share, representing a decline of over 60% from the offering price [7]. Group 2: Investor Communication and Support - The firm encourages anyone with information regarding Navan's conduct, including whistleblowers and former employees, to contact them [9]. - Investors who purchased securities in connection with Navan's IPO are encouraged to discuss their legal rights with Faruqi & Faruqi [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Picard Medical, Inc. due to allegations of securities law violations, encouraging affected investors to participate in a class action lawsuit [4][6]. Group 1: Legal Investigation and Class Action - The law firm is reminding investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Picard Medical [4]. - Allegations against Picard Medical include involvement in a fraudulent stock promotion scheme, insider trading, and misleading public statements regarding the company's financial health [6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Picard Medical's conduct [9]. Group 2: Stock Performance and Impact - On October 24, 2025, Picard Medical's shares experienced a significant decline, closing at $5.31, down from $13.20 the previous day, marking a drop of $7.89 per share or approximately 59.8% [7].

Core Viewpoint - Varonis Systems, Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding its business performance and customer retention capabilities, leading to significant financial losses for investors [1][2]. Company Overview - Varonis Systems, Inc. (NASDAQ: VRNS) is under investigation by Faruqi & Faruqi, LLP for potential securities fraud claims [1]. - The company is accused of failing to disclose material adverse facts about its ability to convert existing customers to its SaaS offerings, which has negatively impacted its Annual Recurring Revenue (ARR) growth potential [1]. Financial Performance - On October 28, 2025, Varonis reported third-quarter fiscal 2025 results, revealing a significant miss in ARR and a reduction in full-year guidance, despite having previously raised guidance for two consecutive quarters [1]. - The company attributed its disappointing results to weaker-than-expected renewals and conversions in its subscription business, leading to the announcement of a 5% headcount reduction and the end of life for its self-hosted solution [1]. Stock Market Reaction - Following the announcement of its financial results, Varonis' stock price plummeted from $63.00 per share on October 28, 2025, to $32.34 per share on October 29, 2025, marking a decline of approximately 48.67% in just one day [1].